Dicerna Pharmaceuticals Inc Logo Image

Dicerna Pharmaceuticals Inc

Most Recent Annual Report

2017 Annual Report and Form 10K

Dicerna Pharmaceuticals Inc

Dicerna Pharmaceuticals Inc has reached its limit for free report views.

Dicerna Pharmaceuticals Inc does not currently have any hardcopy reports on AnnualReports.com. Click the button below to request a report when hardcopies become available.

Archived Annual Reports

About Dicerna Pharmaceuticals Inc

11-50 Employees
Based in Cambridge, Massachusetts

Dicerna Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for liver diseases and cancers based on a proprietary RNA interference technology platform in the United States and internationally. The company’s development programs include DCR-PH1 for the treatment of primary hyperoxaluria type 1 (PH1) through targeting the gene encoding the liver enzyme glycolate oxidase; and other rare inherited diseases involving genes expressed in the liver.

Ticker:
DRNA
Exchange:
NASDAQ (See More NASDAQ Companies)
Industry:
Biotechnology (See More Biotechnology Companies)
Sector:
Healthcare (See More Healthcare Companies)

Looking for Other Annual Reports?

Search by company name or ticker symbol

Filter by: